A retrospective cohort study using data from 103 healthcare organizations compared 454 pulmonary arterial hypertension patients receiving sotatercept to 963.386 pulmonary arterial hypertension patients not receiving sotatercept. After propensity score matching to balance baseline characteristics, 346 patients per group were analyzed over an average follow-up of approximately 6-8 months.
The sotatercept group demonstrated dramatically lower all-cause mortality compared to controls (3.2% versus 30.4%, representing a 27.2% absolute risk reduction). Kaplan-Meier survival analysis confirmed superior survival rates (95.5% versus 45.2%). No lung transplantation events occurred in the sotatercept group, and the composite safety endpoint was significantly lower (10.2% versus 26.9%).
This large real-world analysis provides evidence that sotatercept use in pulmonary arterial hypertension patients is associated with markedly improved survival, absence of lung transplantation events, and fewer adverse outcomes compared to standard treatment, confirming the therapeutic benefits observed in clinical trials translate effectively to routine clinical practice.
Read the abstract of the article at this link on the International Journal of Cardiology
Citation
Naeem A, Bolaji O, Kidess GG, Fahed J, Jahan S, Basit J, Khan MH, Mangeshkar S, Sorci S, Kassis-George H, Dani S, Alraies C. Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. Int J Cardiol. 2026 Jan 2:134150. doi: 10.1016/j.ijcard.2025.134150. Epub ahead of print. PMID: 41485617.